ArticleAnnals of surgical oncology2026
The Survival for Pneumonectomy After Neoadjuvant Therapy in Non-small Cell Lung Cancer: A Retrospective Study from the National Cancer Center in China.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate the impact of pneumonectomy after neoadjuvant therapy by assessing postoperative outcomes, survival prognosis, and recurrence patterns.
methodsA retrospective analysis of patients with non-small cell lung cancer (NSCLC) who underwent pneumonectomy between January 2017 and December 2022 was performed. The patients were divided into two groups based on whether they received neoadjuvant therapy, resulting in the neoadjuvant therapy group and the non-neoadjuvant therapy group. Propensity score-matching was performed to balance the cohorts. Perioperative outcomes, survival outcomes, and recurrence patterns were compared between the two groups.
resultsThe entire cohort comprised 455 patients. Using a 2:1 propensity score-matching method, 229 patients in the non-neoadjuvant therapy group and 137 patients in the neoadjuvant therapy group were enrolled in the subsequent analysis. Univariate logistic regression analysis showed that postoperative intensive care unit (ICU) stay, open thoracotomy, operation time, intraoperative blood transfusion, and postoperative hospital stay were risk factors for postoperative complications. The neoadjuvant therapy group had a longer postoperative ICU stay (6.1% vs 12.4%; P = 0.036). However, postoperative morbidity did not differ significantly between the two groups (P = 0.134). The pathologic complete response rate for the patients receiving chemoimmunotherapy was significantly higher than for those receiving chemotherapy alone. Subgroup analyses indicated that only neoadjuvant chemoimmunotherapy significantly improved overall survival (hazard ratio [HR], 0.34; range, 0.14-0.85; P = 0.020).
conclusionThe study confirmed that neoadjuvant therapy was safe and effective for patients with pneumonectomy, and that neoadjuvant chemoimmunotherapy had a favorable impact on patient prognosis.
Indexed as
Identifiers
41083835What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.